Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cardiol Therapeutics Inc T.CRDL

Alternate Symbol(s):  CRDL

Cardiol Therapeutics Inc. is a clinical-stage life sciences company. The Company is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. It is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. It has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart.


TSX:CRDL - Post by User

Post by Youhillmanon Aug 03, 2021 11:05am
249 Views
Post# 33642250

August Corporate Presentation

August Corporate Presentation

Nice to see this month's Investor Presentation already posted on the first business day of the month.

The share price is very stagnant right now, a catalyst is needed to get the SP moving again.

August tends to be a slow month in the markets, so I'm guessing the NASDAQ listing approval will be announced in September, when this occurs I can see the SP doubling.

Waiting to hear more about the covid trials as we are 3-4 months into it, I'm surprised we haven't heard anymore from Cardiol on this trial, wth Covid still being a major issue I would think the Covid trials are as relevant as ever for the FDA. 

I'm long on CRDL!

Here's the link to the corporate presentation.

https://www.cardiolrx.com/wp-content/uploads/2021/08/Cardiol-Therapeutics-Inc.-Corporate-Presentation-August-2021.pdf

<< Previous
Bullboard Posts
Next >>